Xanthine oxidase inhibitory kinetics and mechanism of ellagic acid: In vitro, in silico and in vivo studies

IET Nanobiotechnol. 2023 Jun;17(4):368-375. doi: 10.1049/nbt2.12135. Epub 2023 May 8.

Abstract

Ellagic acid (EA), which is widely distributed in many foods, has been found to possess inhibitory activity against xanthine oxidase (XO). However, there is ongoing debate about the difference in XO inhibitory activity between EA and allopurinol. Additionally, the inhibitory kinetics and mechanism of EA on XO are still unclear. Herein, the authors systematically studied the inhibitory effects of EA on XO. The authors' findings showed that EA is a reversible inhibitor with mixed-type inhibition, and its inhibitory activity is weaker than allopurinol. Fluorescence quenching experiments suggested that the generation of EA-XO complex was exothermic and spontaneous. In silico analysis further confirmed that EA entered the XO catalytic centre. Furthermore, the authors verified the anti-hyperuricemia effect of EA in vivo. This study elucidates the inhibition kinetics and mechanism of EA on XO, and lays a theoretical foundation for the further development of drugs and functional foods containing EA for the treatment of hyperuricemia.

Keywords: biochemistry; biological techniques; drugs; enzymes.

MeSH terms

  • Allopurinol* / pharmacology
  • Allopurinol* / therapeutic use
  • Ellagic Acid / pharmacology
  • Ellagic Acid / therapeutic use
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Hyperuricemia* / drug therapy
  • Kinetics
  • Xanthine Oxidase / metabolism
  • Xanthine Oxidase / therapeutic use

Substances

  • Allopurinol
  • Enzyme Inhibitors
  • Xanthine Oxidase
  • Ellagic Acid